Tenon Medical, Inc. - TNON STOCK NEWS

Tenon Medical (NASDAQ: TNON), a company focused on Sacroiliac Joint (SIJ) disorders treatment, has scheduled its Q3 2024 financial results release for November 13, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day, featuring a Q&A session with covering analysts. The call will be accessible via phone (1-800-717-1738 US, 1-646-307-1865 International) and webcast. A replay will be available through November 27, 2024, via the company's IR website or telephone.

Tenon Medical (NASDAQ:TNON), a company focused on Sacroiliac Joint (SIJ) disorders treatment, has announced full compliance with all Nasdaq continued listing requirements. The company has successfully addressed previous non-compliance issues related to independent directors, board committees, minimum bid price, public float shares, and stockholders' equity. Nasdaq has provided written confirmation of the company's renewed compliance status.

Tenon Medical, Inc. (NASDAQ:TNON) has announced the issuance of three new U.S. patents, further strengthening its international patent portfolio for Sacroiliac Joint (SIJ) stabilization systems. The patents include:

1. U.S. Patent Nos. 12,115,075 and 12,115,076: Enhanced Catamaran® prostheses with unique drug delivery compositions for improved sealing and bone growth.

2. U.S. Patent No. 12,115,077: SI joint prostheses designed to correct failed SI joint stabilization without removing the failed implant.

These additions bring Tenon's patent portfolio for the Catamaran® SI Joint Fusion System to 12 issued U.S. and foreign patents, with 23 pending applications. The company views these patents as reinforcing its focus on innovation and strengthening its competitive position in the industry.

Tenon Medical (NASDAQ:TNON) has announced the issuance of three Notices of Allowance from the USPTO for patent applications related to their Catamaran® SI Joint Fusion System. Two applications focus on unique drug delivery compositions for bone growth, while the third addresses correcting failed SI joint stabilization without removing the failed implant.

These additions will expand Tenon's patent portfolio to 9 granted patents and 26 pending applications worldwide. Richard Ginn, Co-Founder and CTO, emphasized the importance of intellectual property protection in their growth strategy and commitment to innovation in SI joint treatment.

Tenon Medical, Inc. (NASDAQ:TNON), a company focused on sacroiliac joint disorders, has closed a $4.5 million public offering. The offering, priced at-the-market under Nasdaq rules, included 1,222,850 shares of common stock (or pre-funded warrants) and warrants to purchase up to 1,222,850 additional shares. The combined offering price was $3.68 per share and accompanying warrant. The warrants have an exercise price of $3.55 per share, are immediately exercisable, and will expire in five years. A.G.P./Alliance Global Partners acted as the sole placement agent for this offering, which was conducted under a Form S-1 registration statement.

Tenon Medical, Inc. (NASDAQ:TNON), a company focused on sacroiliac joint disorders, has announced the pricing of a $4.5 million public offering. The offering includes up to 1,222,850 shares of common stock (or pre-funded warrants) and warrants to purchase up to 1,222,850 shares at a combined price of $3.68 per share and accompanying warrant. The warrants have an exercise price of $3.55 per share, are immediately exercisable, and expire in five years. The offering, priced at-the-market under Nasdaq rules, is expected to close around September 16, 2024. Tenon plans to use the net proceeds for commercial activity, working capital, and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering.

Tenon Medical (NASDAQ:TNON) has announced the alpha launch of its new Catamaran SE SI Joint Fusion System, scheduled for early Q4. This system features a 30% smaller implant compared to the original Catamaran device, offering physicians more options for smaller SI joint anatomy or revising previously treated joints. The SE system also includes a manual drilling option.

Key points:

• Catamaran SE provides choices for varying anatomy and treatment strategies
• Over 700 Catamaran fixation devices have been implanted to date
• The system is based on AO principles of arthrodesis
• Recent positive interim outcomes from the MAINSAIL Study were published

The alpha launch will gather initial user feedback before a broader market introduction.

Tenon Medical (NASDAQ:TNON), a company focused on sacroiliac joint disorders, has announced a 1:8 reverse stock split effective September 6, 2024. This strategic move aims to increase the per-share market price to meet Nasdaq's minimum $1.00 average closing price requirement for continued listing. The split, approved by stockholders on December 21, 2023, will convert each 8 shares of issued and outstanding common stock into one share. Trading on a split-adjusted basis will commence on September 6, 2024, under the existing symbol TNON. Vstock Transfer, is acting as the exchange agent, managing the process for stockholders with various holding arrangements. No fractional shares will be issued, with all fractions rounded up to the next whole share.

Tenon Medical (NASDAQ:TNON) has published interim results from its MAINSAIL study, evaluating the Catamaran SI Joint Fusion System for treating sacroiliac joint disorders. The study, involving 33 patients across six US clinical sites, showed significant improvements in pain and disability scores at 6 months post-procedure:

- Mean VAS pain scores decreased from 80.9mm to 31.1mm (p<0.001)
- ODI scores improved from 51.9% to 29.6% (p<0.01)
- 93.3% of patients reported high satisfaction at 6 months
- No serious adverse events or reoperations reported

Additionally, 4 out of 6 patients showed evidence of fusion at 12 months. The Catamaran system, designed for minimally invasive SI joint fixation, has been used in 700 procedures to date. The study is ongoing, with a target enrollment of up to 50 patients and follow-up for up to 24 months.